Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Induction SBRT and Olaparib Followed by Pembrolizumab/Olaparib in Gastric and GEJ Cancers
NCT05379972Phase 2Completed
- Sponsor
- University of Colorado Denver
- Start
- Jan 2023
- Primary completion
- Feb 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of olaparib, pembrolizumab in gastric cancer (GC), gastroesophageal junction cancer, sponsored by University of Colorado Denver. Started Jan 2023; status: completed.
02
Drugs
olaparibpembrolizumab
03
Conditions
gastric cancer (GC)gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT05379972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05379972.